Research Article

Mining Database for the Clinical Significance and Prognostic Value of ESRP1 in Cutaneous Malignant Melanoma

Baihe Wang,1 Yang Li,2 Caixia Kou,1 Jianfang Sun,1,2 and Xiulian Xu1

1Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, 12 Jiangwangmiao Street, Nanjing 210042, China
2Department of Dermatology, The Affiliated Qingdao Municipal Hospital of Qingdao University, Qingdao, China

Correspondence should be addressed to Jianfang Sun; loveni86@126.com and Xiulian Xu; 1012336560@qq.com

Received 23 March 2020; Accepted 5 August 2020; Published 7 September 2020

Academic Editor: Adam Reich

Copyright © 2020 Baihe Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Epithelial splicing regulatory protein 1 (ESRP1) has been described as an RNA-binding protein involved in cancer development. However, the expression and regulatory network of ESRP1 in cutaneous malignant melanoma (CMM) remain unclear. Methods. From the sequencing data of 103 CMM samples in The Cancer Genome Atlas database, the expression level of ESRP1 and its correlation with the clinicopathological characteristics were analyzed using the Oncomine 4.5, Gene Expression Profiling Interactive Analysis (GEPIA), and UALCAN tools, while LinkedOmics was used to identify differential gene expression with ESRP1 and to analyze Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Gene enrichment analysis examined target networks of kinases, miRNAs, and transcription factors. Finally, TIMER was used to analyze the relationship between ESRP1 and tumor immune cell infiltration. Results. We found that ESRP1 was lowly expressed in CMM tissues, and a low level of ESRP1 expression correlated with better overall survival. Expression of this gene was linked to functional networks involving the condensed chromosomes, epidermal development, and translation initiation. Functional network analysis suggested that ESRP1 regulated ribosome metabolism, drug metabolism, and chemical carcinogenesis via pathways involving several cancer-related kinases, miRNAs, and transcription factors. Furthermore, our results suggested that ESRP1 played an important role in regulating tumor-associated macrophage polarization, dendritic cell infiltration, Treg cells, and T cell exhaustion. Conclusion. Our study demonstrates ESRP1 expression, prognostic value, and potential regulatory networks in CMM, thereby shedding light on the clinical significance of ESRP1, and provides a novel biomarker for determining prognosis and immune infiltration in CMM.

1. Introduction

Melanoma, a common malignant tumor originating from skin melanocytes, is characterized by high invasiveness [1–3]. According to statistics, there are approximately 200,000 newly diagnosed cases each year [4], and melanoma accounts for 80% of deaths related to cutaneous cancers [5]. In the early stages of melanoma, surgery may be an adequate treatment for patients [6]. However, in the late stages of the disease, patients may develop local or distant metastases with a poor prognosis [7]. Therefore, identifying molecular targets related to tumorigenesis and development is of great significance for the treatment of melanoma.

Epithelial splicing regulatory protein 1 (ESRP1) was previously called RBM35A. The gene is located on chromosome 8q22.1, with a sequence length of 2046 bp and a relative molecular weight of $78 \times 10^3$, encoding 682 amino acids. As a member of the hnRNP family, ESRP1 plays a vital role in organ formation, including craniofacial and epidermal development, branching morphogenesis of the lungs, and salivary gland development. Recent studies have found that ESRP1 regulates the alternative splicing of multiple genes, including CD44, CTNNBD1, ENAH, and FGFR2, thereby affecting intercellular adhesion, cytoskeleton, and cell migration [8, 9]. Hence, ESRPs contribute to the loss of cell differentiation, which is one of the underlying mechanisms of tumorigenesis. In fact, studies have shown that in multiple tumor cell lines,
such as those of prostate cancer, breast cancer, pancreatic cancer, kidney cancer, and head squamous cell carcinoma, tumor invasion is associated with a low expression of ESRPs [10, 11]. However, the specific role of ESRP1 in cutaneous melanoma remains unclear.

In this study, we aimed to systematically explore the gene expression, prognostic values, immune correlations, and potential functions of ESRP1 in CMM. The correlation between ESRP1 levels, clinical parameters, and tumor immune infiltration was comprehensively analyzed. Moreover, we also explored the prognostic value and functions of ESRP1 in CMM. These findings suggest that ESRP1 plays an important role in the clinical prognosis and immune regulation of CMM.

2. Materials and Methods

2.1. Oncomine 4.5. Oncomine 4.5 (http://www.oncomine.org) is a large oncogene chip database and integrated data mining platform, containing 715 datasets and 86733 samples that is established for collecting, standardizing, analyzing, and delivering cancer transcriptome data [12]. In the current study, the level of ESRP1 in melanoma was analyzed using Oncomine 4.5, with a P value of 0.05, a fold change of 2, and a gene rank in the top 10%.

2.2. GEPIA. GEPIA (http://gepia.cancer-pku.cn), a freely available comprehensive web-based tool, analyzes expression data at the transcriptional level with 9,736 tumors and 8,587 normal samples from TCGA and GTEx projects. GEPIA was used to analyze the expression and prognostic value of ESRP1 in melanoma.

2.3. UALCAN. UALCAN (http://ualcan.path.uab.edu) is a newly developed interactive web server for facilitating tumor subgroup gene expression analyses based on data from TCGA and MET500 [13]. The correlation between the level

---

**Figure 1:** ESRP1 expression level in CMM. (a) Increased or decreased ESRP1 in data sets of different cancers compared to that of normal tissues (Oncomine). (b, c) The expression of ESRP1 was significantly downregulated in the CMM tissue compared to that in the normal tissue (TCGA and GEPIA).
2.4. LinkedOmics. LinkedOmics (http://www.linkedomics.org) is a flexible, user-friendly portal providing analysis and comparison of cancer multiomics data across 32 TCGA tumor types [14]. We first explored the correlated significant genes of ESRP1 in 103 TCGA CMM samples using the Link-Finder module. Pearson’s correlation coefficient was used to analyze the results, which were graphically presented in volcano plots, heat maps, or scatter plots. Gene set enrichment analysis (GSEA) was performed with a minimum number of genes of 3 and a simulation of 500.

2.5. GeneMANIA. GeneMANIA (http://www.genemania.org) is a flexible portal that can analyze the functions of gene lists and find neighboring genes by constructing a protein-protein interaction (PPI) network [15]. GeneMANIA was
3. Results

3.1. Expression Level of ESRP1 in Patients with CMM. The expression of ESRP1 was significantly downregulated in CMM tissues compared to normal tissues, based on the data from Oncomine 4.5 (Figures 1(a) and 1(b), P < 0.05). Data from Riker et al. [20] has also revealed that ESRP1 was significantly decreased in CMM tissues with a fold change of -4.472 (Figure 1(b)). Moreover, GEPIA analysis suggested that ESRP1 is linked to functional networks involving the condensed chromosome, epidermis development, and translational initiation (Figures 5(a)–5(c)). Moreover, functional network analysis suggested that ESRP1 regulates the ribosome, drug metabolism, and chemical carcinogenesis (Figures 5(d), 6(a), and 6(b)).

3.2. Prognostic Value of ESRP1 in Patients with CMM. We also explored the significance of ESRP1 in the prognosis of patients with CMM. Consequently, we found that the CMM patients in the higher ESRP1 level group had poor overall survival, while patients in the low ESRP1 level group had good overall survival (Figure 3(a), P = 0.0023). However, there was no significant difference between the high ESRP1 level group and the low ESRP1 level group with regard to disease-free survival (Figure 3(b), P = 0.18).

3.3. Enrichment Analysis of ESRP1 in CMM. As shown in Figure 4(a), a positive correlation was obtained between ESRP1 and 788 genes (FDR < 0.05). In contrast, 243 genes (dark green dots) showed a negative correlation with ESRP1 (FDR < 0.05). The top 50 significant genes that positively and negatively correlated with ESRP1 are shown in Figure 4(b) and 4(c), respectively.

Figure 4: Genes differentially expressed in correlation with ESRP1 in CMM (LinkedOmics). (a) A Pearson test was used to analyze correlations between ESRP1 and genes differentially expressed in CMM. (b, c) Heat maps showing the top 50 significantly positively and negatively correlated with ESRP1 in CMM. Red indicates positively correlated genes, and green indicates negatively correlated genes.
3.4. Kinase, miRNA, and Transcription Factor Target Networks of ESRP1 in CMM. We found that the top 5 significant kinase target networks related to ESRP1 were cyclin-dependent kinase 1 (CDK1), G protein-coupled receptor kinase 3 (GRK3), protein kinase cAMP-activated catalytic subunit beta (PRKACB), protein kinase cAMP-activated catalytic subunit gamma (PRKACG), and protein kinase, X-linked (PRKX) (Table 1). The top 5 miRNA target networks were CACCAGC, miR-138; ATGAAGG, miR-205; GACAATC, miR-423 (Table 1). The top 5 transcription factor target networks were CACCAGC, miR-138; ATGAAGG, miR-205; GACAATC, miR-423 (Table 1). The top 5 transcription factor target networks were CACCAGC, miR-138; ATGAAGG, miR-205; GACAATC, miR-423 (Table 1).
among genes for the kinases CDK1, miRNA-138, and ETF_Q6. As a result, the gene set enriched for kinase CDK1 was involved in the regulation of mitosis, nuclear division, organelle fission, microtubule cytoskeleton organization, and chromosome segregation (Figure 7). The gene set enriched for miR-138 was responsible for the regulation of membrane depolarization, regulation of membrane potential, monovalent inorganic cation transport, monovalent inorganic cation transmembrane transporter activity, and inorganic cation transmembrane transporter activity (Supplementary Figure 2). In addition, the gene set enriched for ETF_Q6 was mainly involved in amino acid regulation, cellular response to amino acid stimulus, negative regulation of intracellular signal transduction, cellular response to acids, TOR signaling, and positive regulation of CREB transcription factor activity (Supplementary Figure 3).

3.5. The Potential of ESRP1 as an Immune Biomarker in CMM.

As shown in Figure 8, the expression of ESRP1 was negatively associated with the infiltration abundance of B cells (Cor = −0.262, P = 1.76e−08), CD8+ T cells (Cor = −0.195, P = 3.83e−05), CD4+ T cells (Cor = −0.165, P = 4.51e−04), macrophages (Cor = 0.301, P = 5.68e−151), neutrophils (Cor = 0.289, P = 3.69e−10), and dendritic cells (DCs; Cor = −0.281, P = 1.54e−09).

In order to analyze the potential of ESRP1 as an immune biomarker in CMM, we further analyzed the association between ESRP1 and immune cells. As expected, after adjusting for purity, the data demonstrated a strong association between ESRP1 levels and most immune biomarkers of a variety of immune cells and different T cells in CMM (Table 2).

Specifically, the expression level of ESRP1 was significantly associated with most marker sets of monocytes,

---

**Table 1:** The kinase, miRNA and transcription factor target networks of ESRP1 in CMM (LinkedOmics).

| Enriched category | Gene set | Leading edge no. | P value |
|-------------------|----------|------------------|---------|
| Kinase target     | Kinase_CDK1 | 85               | 0.0001  |
|                   | Kinase_GRK3  | 51               | 0.0001  |
|                   | Kinase_PRKACB | 28              | 0.0001  |
|                   | Kinase_PRKACG | 27              | 0.011   |
|                   | Kinase_PRKX   | 27               | 0.011   |
| miRNA target      | CACCAGC, miR-138 | 45           | 0.0001  |
|                   | ATGAAGG, miR-205 | 38           | 0.015   |
|                   | GACAATC, miR-219 | 26           | 0.033   |
|                   | ACAACCT, miR-453 | 12           | 0.034   |
|                   | ACCGAGC, miR-423 | 3            | 0.007   |
| Transcription factor target | V$ETF_Q6 | 48               | 0.0001  |
|                   | V$E2F_Q2     | 32               | 0.0001  |
|                   | V$SEN1_01    | 40               | 0.0001  |
|                   | V$SUSF2_Q6   | 27               | 0.0001  |
|                   | V$CEBPB_01   | 24               | 0.012   |

---

**Figure 6:** KEGG pathway (LinkedOmics). (a) KEGG pathway annotations of the ribosome metabolism. (b) KEGG pathway annotations of the drug metabolism. Red marked nodes are associated with the leading edge gene.
TAMs, and M2 macrophages, revealing that ESRP1 may mediate macrophage polarization in CMM. Moreover, low ESRP1 expression is related to high infiltration levels of DCs in CMM. A significant correlation was obtained between ESRP1 expression and expression of DC biomarkers such as HLA-DPB1, BDCA-1, BDCA-4, and CD11c, thus demonstrating a strong relationship between ESRP1 and DC infiltration. In addition, ESRP1 expression negatively correlated with FOXP3, CCR8, STAT5B, and TGFβ1 in CMM for Treg cells. Furthermore, ESRP1 expression
negatively correlated to PDCD1 (PD-1), CTLA4, LAG3, TIM-3, and GZMB in CMM for T cell exhaustion. Previous studies have demonstrated the significant role of PD-1, CTLA4, and TIM-3 in the immunotherapy of various types of cancers [21–23]. Thus, these results suggested the important role of ESRP1 in tumor immune microenvironment.

4. Discussion

CMM is a highly malignant cancer, and metastatic melanoma often leads to a poor prognosis. Nevertheless, its immunogenicity allows intervention via immunotherapeutic strategies such as cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed death-1 (PD-1) inhibitors, which are considered important for the treatment of malignant melanoma [21, 24]. Recently, it has been reported that patients with advanced melanoma achieved a partial response to immunotherapy. Increasing research proved that the levels of tumor-infiltrating lymphocytes (TILs) are associated with response rates to checkpoint blockade in many cancers [25]. Therefore, it is urgent to elucidate the immunophenotypes of tumor-immune interactions as well as immune-related therapeutic targets in CMM.

ESRP1, as a member of an RNA-binding protein family, is an exquisitely epithelial cell-type-specific splicing factor that regulates splicing genes involved in tumor progression [26, 27]. Early onset of an aggressive subgroup of prostate cancer was found to be associated with the expression of ESRP1, indicating that ESRP1 is a potential prognostic marker in prostate cancer [28]. According to Mager LF, the reduced ESRP1 level leads to impaired intestinal barrier integrity, increases susceptibility to colitis, and alters colorectal cancer development [29].

To gain more information about the potential functions of ESRP1 and its regulatory network, we performed target gene analyses of tumor data from public databases. We found that ESRP1 mRNA levels were significantly downregulated in CMM tissues compared to those in normal tissues. Patients with low ESRP1 expression had relatively good overall survival. Related functional networks are involved in epidermal development, translation initiation, ribosome metabolism, drug metabolism, and chemical carcinogenesis. This is consistent with the physiological function of ESRP1 [30]. ESRP1 significantly reduces the growth of tamoxifen-resistant cells and changes epithelial-mesenchymal transition protein markers by affecting metabolic pathways [31], which is consistent with the findings of bioinformatics analysis.

Enrichment analysis found that ESRP1 in CMM is associated with a network of kinases, including CDK1, GRK3, and PRKACB. These kinases regulate mitosis, cell cycle, and cell proliferation [32, 33]. In fact, CDK1 is the main regulator of the cell cycle. CDK1 overexpression in melanoma cells increases carcinogenic potential and tumor initiation ability. Knocking out Sox2 in CDK1-overexpressed cells can significantly inhibit CDK1; hence, the CDK1-Sox2 interaction is a potential therapeutic target in cancer [34].

miRNAs are small noncoding ribonucleic acid molecules that affect biological processes, including cell proliferation, differentiation, and migration [35, 36]. Our study revealed several miRNAs that were associated with ESRP1, including miRNA-138. Researchers have found that miR-138, miR-155, and miR-221/222 can be used as the diagnostic and prognostic markers of CMM [36–38]. Some studies have reported that miR-138 has tumor-suppressive effects in malignant diseases of the lung, kidney, tongue, head, and neck [39–41].

We found that the top five important transcription factor target networks are ETF, E2F, EN, USF, and CEBPB. ETF, E2F, and SP-1 participate in the cytokine-independent proliferation of mouse hepatocytes [42]. Furthermore, MDM2 relies on the regulation of transcription factor E2F1 to promote the invasion and motility of melanoma cells [43].

Another important aspect of our study is that ESRP1 is negatively related to infiltration of DCs and Treg cells such as FOXP3. It is well known that DCs can promote tumor metastasis by upregulating Treg cells and downregulating CD8+ T cell cytotoxicity [44]. FOXP3 plays a very important role in Treg cells, preventing cytotoxic T cells from attacking tumor cells [24]. Thus, ESRP1 might have the potential to inhibit tumor development by regulating the immunosuppressive microenvironment. Furthermore, in our study, we found that ESRP1 expression was negatively related to T cell exhaustion. T cell exhaustion refers to the loss of functional potential of TILs in the presence of chronic antigens in the tumor microenvironment [45]. Many studies have shown that cellular immune function is decreased when TILs in melanoma tissues express high inhibitory receptors, such as PD-1, CTLA4, and TIM-3 [46–49]. Thus, we speculated that ESRP1 could reflect the immune cell status of tumor patients and could be a predictive target for immunotherapy.
Table 2: Correlation analysis between ESRP1 and related genes and biomarkers of immune cells in CMM (TIMER).

| Description          | Gene markers | None Cor | None P value | CMM Cor | CMM P value | Purity Cor | Purity P value |
|----------------------|--------------|----------|--------------|---------|-------------|------------|----------------|
| CD8+ T cell          | CD8A         | 0.223    | ***          | -0.143  | **          |            |                |
|                      | CD8B         | -0.201   | ***          | -0.114  | *           |            |                |
| T cell (general)     | CD3D         | -0.215   | ***          | -0.125  | **          |            |                |
|                      | CD3E         | -0.227   | ***          | -0.139  | **          |            |                |
|                      | CD2          | -0.226   | ***          | -0.139  | **          |            |                |
| B cell               | CD19         | -0.196   | ***          | -0.128  | **          |            |                |
|                      | CD79A        | -0.185   | ***          | -0.105  | *           |            |                |
| Monocyte             | CD86         | -0.352   | ***          | -0.272  | ***         |            |                |
|                      | CD115(CSF1R) | -0.37    | ***          | -0.325  | ***         |            |                |
| TAM                  | CCL2         | -0.357   | ***          | -0.314  | ***         |            |                |
|                      | CD68         | -0.179   | ***          | -0.121  | **          |            |                |
|                      | IL10         | -0.371   | ***          | -0.325  | ***         |            |                |
| M1 macrophage        | INOS (NOS2)  | -0.057   | 0.219        | -0.046  | 0.326       |            |                |
|                      | IRF5         | -0.279   | ***          | -0.214  | ***         |            |                |
|                      | COX2(PGSS2)  | -0.292   | ***          | -0.273  | ***         |            |                |
| M2 macrophage        | CD163        | -0.363   | ***          | -0.317  | ***         |            |                |
|                      | VSIG4        | -0.346   | ***          | -0.294  | ***         |            |                |
|                      | MS4A4A       | -0.326   | ***          | -0.266  | ***         |            |                |
| Neutrophils          | CD66b (CEACAM8) | -0.042  | 0.361        | -0.054  | 0.251       |            |                |
|                      | CD11b (ITGAM) | -0.366  | ***          | -0.317  | ***         |            |                |
|                      | CCR7         | 0.215    | ***          | -0.137  | *           |            |                |
| Natural killer cell  | KIR2DL1      | -0.156   | **           | -0.074  | 0.113       |            |                |
|                      | KIR2DL3      | -0.197   | ***          | -0.119  | *           |            |                |
|                      | KIR2DL4      | -0.167   | ***          | -0.085  | 0.068       |            |                |
| Dendritic cell       | KIR3DL1      | -0.188   | ***          | -0.11   | *           |            |                |
|                      | KIR3DL2      | -0.232   | ***          | -0.152  | **          |            |                |
|                      | KIR3DL3      | -0.046   | 0.317        | -0.012  | 0.795       |            |                |
|                      | KIR2DS4      | -0.12    | **           | -0.052  | 0.268       |            |                |
|                      | HLA-DPB1     | -0.253   | ***          | -0.174  | ***         |            |                |
|                      | HLA-DQB1     | -0.259   | ***          | -0.191  | ***         |            |                |
|                      | HLA-DRA      | -0.276   | ***          | -0.206  | ***         |            |                |
|                      | HLA-DPA1     | -0.256   | ***          | -0.186  | ***         |            |                |
|                      | BDC1-1(CD1C) | -0.227   | ***          | -0.161  | ***         |            |                |
|                      | BDC1-4(NRP1) | 0.414    | **           | -0.388  | ***         |            |                |
|                      | CD11c (ITGAX)| -0.242   | ***          | -0.171  | ***         |            |                |
| Th1                  | T-bet (TBX21)| -0.242   | ***          | -0.159  | ***         |            |                |
|                      | STAT4        | 0.204    | ***          | -0.122  | **          |            |                |
|                      | STAT1        | 0.144    | **           | -0.075  | 0.111       |            |                |
|                      | IFN-g (IFNG) | -0.22     | ***          | -0.144  | **          |            |                |
|                      | TNF-a (TNF)  | -0.151   | **           | -0.055  | 0.241       |            |                |
Our study provides a multilevel evidence for the role and potential of ESPR1 as a molecular marker in CMM. However, further studies are required to validate our findings and thus promote the clinical utility of ESRP1 serving as a prognostic indicator or immunotherapy target in CMM.

5. Conclusion

In summary, our study highlights the potential utility of ESRP1 status in predicting response to checkpoint blockade immunotherapy and could be a prognosis biomarker in patients with CMM.

Data Availability

The analyzed data sets generated during the study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

Baihe Wang designed the study and wrote the manuscript. Yang Li and Caixia Kou helped to analyze the data. Jianfang Sun and Xiulian Xu are involved in manuscript review and editing and supervision of the entire work. All authors read and approved the final manuscript.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81772916), Jiangsu Natural Science Foundation (BK20171132), and the CAMS Innovation Fund for Medical Sciences (CIFMS-2017-I2M-1-017).

Supplementary Materials

Supplementary Figure 1: gene expression correlation analysis for ESRP1 and significant correlated genes (LinkedOmics). The scatter plot shows Pearson’s correlation of ESRP1 expression with expression of XG (A), DMKN (B), GPR1 (C), RGS8 (D), SLC22A6 (E), and OGG1 (F). Supplementary Figure 2: PPI network of miR-138 miRNA target networks (GeneMANIA). PPI network and functional analysis indicating the gene set that was enriched in the target network of miR-138. Different colors of the network edge indicate the bioinformatics methods applied: coexpression, website prediction, pathway, physical interactions, and colocalization. The different colors for the network nodes indicate the biological functions of the set of enrichment genes.
Supplementary Table 1: significantly enriched CDK1 kinase target network of ESRP1 in skin cutaneous melanoma (LinkedOmics). Supplementary Table 2: significantly enriched miR-138 miRNA target networks of ESRP1 in skin cutaneous melanoma (LinkedOmics). Supplementary Table 3: significantly enriched ETF_Q6 transcription factor target networks of ESRP1 in skin cutaneous melanoma (LinkedOmics).

(Supplementary materials)

References

[1] D. N. Silvers, “Focus on melanoma,” The Journal of Dermatologic Surgery, vol. 2, no. 2, pp. 108–110, 1976.

[2] J. D. Wolchok and Y. M. Saenger, “Current topics in melanoma,” Current Opinion in Oncology, vol. 19, no. 2, pp. 116–120, 2007.

[3] A. Uong and L. I. Zon, “Melanocytes in development and cancer,” Journal of Cellular Physiology, vol. 222, no. 1, pp. 38–41, 2010.

[4] D. E. Elder, “Melanoma progression,” Pathology, vol. 48, no. 2, pp. 147–154, 2016.

[5] A. C. Green and M. G. O’Rourke, “Cutaneous malignant melanoma in association with other skin cancers,” Journal of the National Cancer Institute, vol. 74, no. 5, pp. 977–980, 1985.

[6] F. J. Lejeune, “The impact of surgery on the course of melanoma,” Recent Results in Cancer Research, vol. 160, pp. 151–157, 2002.

[7] L. Finn, S. N. Markovic, and R. W. Joseph, “Therapy for metastatic melanoma: the past, present, and future,” BMC Medicine, vol. 10, no. 1, 2012.

[8] C. C. Warzecha, P. Jiang, K. Amirikian et al., “An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition,” The EMBO Journal, vol. 29, no. 19, pp. 3286–3300, 2010.

[9] H. Ishii, M. Saitoh, K. Sakamoto et al., “Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms,” The Journal of Biological Chemistry, vol. 289, no. 40, pp. 27386–27399, 2014.

[10] K. Horiguchi, K. Sakamoto, D. Koinuma et al., “TGF-β drives epithelial-mesenchymal transition through βEF1-mediated downregulation of ESRP,” Oncogene, vol. 31, no. 26, pp. 3190–3201, 2012.

[11] J. Ueda, Y. Matsuda, K. Yamahatsu et al., “Epithelial splicing regulatory protein 1 is a favorable prognostic factor in pancreatic cancer that attenuates pancreatic metastases,” Oncogene, vol. 33, no. 36, pp. 4485–4495, 2014.

[12] D. R. Rhodes, S. Kalyana-Sundaram, V. Mahavisno et al., “Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles,” Neoplasia, vol. 9, no. 2, pp. 166–180, 2007.

[13] D. S. Chandrashekar, B. Bashel, S. A. H. Balasubramanaya et al., “UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses,” Neoplasia, vol. 19, no. 8, pp. 649–658, 2017.

[14] S. V. Vasaikar, P. Straub, J. Wang, and B. Zhang, “LinkedOmics: analyzing multi-omics data within and across 32 cancer types,” Nucleic Acids Research, vol. 46, no. D1, pp. D956–D963, 2018.

[15] M. Franz, H. Rodriguez, C. Lopes et al., “GeneMANIA update 2018,” Nucleic Acids Research, vol. 46, no. W1, pp. W60–W64, 2018.

[16] T. Li, J. Fan, B. Wang et al., “TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells,” Cancer Research, vol. 77, no. 21, pp. e108–e110, 2017.

[17] N. O. Siemers, J. L. Holloway, H. Chang et al., “Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors,” PloS one, vol. 12, no. 7, article e0179726, 2017.

[18] P. Danaher, S. Warren, L. Dennis et al., “Gene expression markers of tumor infiltrating leukocytes,” Journal for Immunotherapy of Cancer, vol. 5, no. 1, 2017.

[19] S. Sousa and J. Maatta, “The role of tumour-associated macrophages in bone metastasis,” Journal of bone oncology, vol. 5, no. 3, pp. 135–138, 2016.

[20] A. I. Riker, S. A. Enkemann, O. Fodstad et al., “The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis,” BMC Medical Genomics, vol. 1, no. 1, p. 13, 2008.

[21] J. Gong, A. Chehrazi-Raffle, S. Reddi, and R. Salgia, “Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations,” Journal for Immunotherapy of Cancer, vol. 6, no. 1, p. 8, 2018.

[22] T. A. Waldmann and J. Chen, “Disorders of the JAK/STAT pathway in T cell lymphoma pathogenesis: implications for immunotherapy,” Annual Review of Immunology, vol. 35, no. 1, pp. 533–550, 2017.

[23] M. Das, C. Zhu, and V. K. Kuchroo, “Tim-3 and its role in regulating anti-tumor immunity,” Immunological Reviews, vol. 276, no. 1, pp. 97–111, 2017.

[24] A. Facciabene, G. T. Motz, and G. Coulkos, “T-regulatory cells: key players in tumor immune escape and angiogenesis,” Cancer Research, vol. 72, no. 9, pp. 2162–2171, 2012.

[25] Q. Zeng, W. Zhang, X. Li, J. Lai, and Z. Li, “Bioinformatic identification of renal cell carcinoma microenvironment-associated biomarkers with therapeutic and prognostic value,” Life Sciences, vol. 243, article 117273, 2020.

[26] K. A. Dittmar, P. Jiang, J. W. Park et al., “Genome-wide determination of a broad ESRP-regulated posttranscriptional network by high-throughput sequencing,” Molecular and Cellular Biology, vol. 32, no. 8, pp. 1468–1482, 2012.

[27] X. Yang, J. Coulombe-Huntington, S. Kang et al., “Widespread expansion of protein interaction capabilities by alternative splicing,” Cell, vol. 164, no. 4, pp. 805–817, 2016.

[28] J. W. Russo and S. P. Balk, “Initiation and evolution of early onset prostate cancer,” Cancer Cell, vol. 34, no. 6, pp. 874–876, 2018.

[29] L. F. Mager, V. H. Koelzer, R. Stuber et al., “The ESRP1-GPR137 axis contributes to intestinal pathogenesis,” eLife, vol. 6, article e28366, 2017.

[30] T. W. Bebee, J. W. Park, K. I. Sheridan et al., “The splicing regulators Esrp1 and Esrp2 direct an epithelial splicing program essential for mammalian development,” eLife, vol. 4, 2015.

[31] Y. Gokmen-Polar, Y. Neelamraju, C. P. Goswami et al., “Splicing factor ESRP1 controls ERα-positive breast cancer by altering metabolic pathways,” EMBO Reports, vol. 20, no. 2, 2019.

[32] W. W. Huang, S. C. Tsai, S. F. Peng et al., “Kaempferol induces autophagy through AMPK and AKT signaling molecules and causes G2/M arrest via downregulation of CDK1/cyclin B in SK-HEP-1 human hepatic cancer cells,” International Journal of Oncology, vol. 42, no. 6, pp. 2069–2077, 2013.
[33] H. Nakamura, Y. Arai, Y. Totoki et al., "Genomic spectra of biliary tract cancer," Nature Genetics, vol. 47, no. 9, pp. 1003–1010, 2015.

[34] D. Ravindran Menon, Y. Luo, J. J. Arcaroli et al., "CDK1 interacts with Sox2 and promotes tumor initiation in human melanoma," Cancer Research, vol. 78, no. 23, pp. 6561–6574, 2018.

[35] D. P. Bartel, "MicroRNAs: genomics, biogenesis, mechanism, and function," Cell, vol. 116, no. 2, pp. 281–297, 2004.

[36] A. Gajos-Michniewicz and M. Czyz, "Role of miRNAs in melanoma metastasis," Cancers, vol. 11, no. 3, p. 326, 2019.

[37] A. Martinez-Usatorre, L. F. Sempere, S. J. Carmona et al., "MicroRNA-155 expression is enhanced by T-cell receptor stimulation strength and correlates with improved tumor control in melanoma," Cancer Immunology Research, vol. 7, no. 6, pp. 1013–1024, 2019.

[38] F. Meng, Y. Zhang, X. Li, J. Wang, and Z. Wang, "Clinical significance of miR-138 in patients with malignant melanoma through targeting of PDK1 in the PI3K/AKT autophagy signaling pathway," Oncology Reports, vol. 38, no. 3, pp. 1655–1662, 2017.

[39] H. Zhang, H. Zhang, M. Zhao et al., "miR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer," Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, vol. 31, no. 1, pp. 56–65, 2013.

[40] T. Yamasaki, N. Seki, Y. Yamada et al., "Tumor suppressive microRNA-138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma," International Journal of Oncology, vol. 41, no. 3, pp. 805–817, 2012.

[41] L. Jiang, Y. Dai, X. Liu et al., "Identification and experimental validation of G protein alpha inhibiting activity polypeptide 2 (GNAI2) as a microRNA-138 target in tongue squamous cell carcinoma," Human Genetics, vol. 129, no. 2, pp. 189–197, 2011.

[42] S. Zellmer, W. Schmidt-Heck, P. Godoy et al., "Transcription factors ETF, E2F, and SP-1 are involved in cytokine-independent proliferation of murine hepatocytes," Hepatology, vol. 52, no. 6, pp. 2127–2136, 2010.

[43] M. Verhaegen, A. Checinska, M. B. Ribblett, S. Wang, and M. S. Soengas, "E2F1-dependent oncogenic addiction of melanoma cells to MDM2," Oncogene, vol. 31, no. 7, pp. 828–841, 2012.

[44] A. Sawant, J. A. Hensel, D. Chanda et al., "Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells," Journal of Immunology, vol. 189, no. 9, pp. 4258–4265, 2012.

[45] K. E. Pauken and E. J. Wherry, "Overcoming T cell exhaustion in infection and cancer," Trends in Immunology, vol. 36, no. 4, pp. 265–276, 2015.

[46] C. A. Egelston, C. Avalos, T. Y. Tu et al., "Human breast tumor-infiltrating CD8(+) T cells retain polyfunctionality despite PD-1 expression," Nature Communications, vol. 9, no. 1, p. 4297, 2018.

[47] J. Fourcade, Z. Sun, M. Benallaoua et al., "Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients," The Journal of Experimental Medicine, vol. 207, no. 10, pp. 2175–2186, 2010.